PH22749A - Optically active carbazole and pharmaceutical composition containing same - Google Patents

Optically active carbazole and pharmaceutical composition containing same

Info

Publication number
PH22749A
PH22749A PH30721A PH30721A PH22749A PH 22749 A PH22749 A PH 22749A PH 30721 A PH30721 A PH 30721A PH 30721 A PH30721 A PH 30721A PH 22749 A PH22749 A PH 22749A
Authority
PH
Philippines
Prior art keywords
carbazole
general formula
derivative
pharmaceutical composition
composition containing
Prior art date
Application number
PH30721A
Other languages
English (en)
Inventor
Leinert Herbert
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6199873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH22749(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of PH22749A publication Critical patent/PH22749A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/14—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/20—Free hydroxyl or mercaptan

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PH30721A 1983-05-26 1984-05-25 Optically active carbazole and pharmaceutical composition containing same PH22749A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833319027 DE3319027A1 (de) 1983-05-26 1983-05-26 Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten

Publications (1)

Publication Number Publication Date
PH22749A true PH22749A (en) 1988-11-28

Family

ID=6199873

Family Applications (1)

Application Number Title Priority Date Filing Date
PH30721A PH22749A (en) 1983-05-26 1984-05-25 Optically active carbazole and pharmaceutical composition containing same

Country Status (20)

Country Link
US (4) US4697022A (fr)
EP (1) EP0127099B1 (fr)
JP (2) JPS59222473A (fr)
KR (1) KR860001761B1 (fr)
AT (1) ATE27273T1 (fr)
AU (1) AU551116B2 (fr)
CA (1) CA1259071A (fr)
DE (2) DE3319027A1 (fr)
DK (2) DK169331B1 (fr)
ES (1) ES532838A0 (fr)
FI (1) FI80018C (fr)
GR (1) GR81577B (fr)
HU (1) HU193011B (fr)
IE (1) IE57533B1 (fr)
IL (1) IL71876A (fr)
NO (1) NO164537C (fr)
NZ (1) NZ208254A (fr)
PH (1) PH22749A (fr)
PT (1) PT78633B (fr)
ZA (1) ZA843976B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657929A (en) * 1983-10-25 1987-04-14 Fisons Plc Compounds
DE3540149A1 (de) * 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Verwendung von 1-(benztriazol-4-yloxy)3-(2-(2-methoxyphenoxy) -ethylamino)-2-propanol als antiglaukommittel, optisch aktive r und s isomere dieser substanz, verfahren zur herstellung derselben sowie arzneimittel, die diese substanzen enthalten
DE68913965T2 (de) * 1988-12-26 1994-08-04 Kowa Co Herstellung von glycidyläther.
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
WO1994020096A1 (fr) * 1993-03-05 1994-09-15 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beckman Corporation Limited Procede d'utilisation de carbazolyle-(4)-oxypropanolamine pour inhiber la proliferation de cellules de muscles lisses
US5629345A (en) * 1993-07-23 1997-05-13 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
US5965620A (en) * 1993-07-23 1999-10-12 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
AU3542697A (en) * 1996-07-13 1998-02-09 Boehringer Mannheim Gmbh Pharmaceutical formulations for topical application containing as an active ingredient carbazolyl-(4)-oxy-propanol amine derivate
ES2171839T3 (es) 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
US5808080A (en) * 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
EP0893440A1 (fr) * 1997-07-22 1999-01-27 Roche Diagnostics GmbH Une modification thermodynamique stabilisée de 1-(4-carbazolyloxy)-3[2-(2-methoxyphenoxy)ethylamino]- 2-propanole, un procédé pour sa préparation et une composition pharmaceutique qui la contient
US6730326B2 (en) 1997-07-22 2004-05-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
HU227441B1 (en) * 1997-11-24 2011-06-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing carvedilol, enantiomers and salts thereof
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
US6664284B2 (en) * 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
JP2003528914A (ja) * 2000-04-03 2003-09-30 エフ．ホフマン−ラ ロシュ アーゲー カルベジロールの濃縮溶液
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
MXPA02012795A (es) 2000-06-28 2004-07-30 Teva Pharma Carvedilol.
KR100342659B1 (en) 2000-12-15 2002-07-04 Rstech Co Ltd Chiral polymer salene catalyst and process for preparing chiral compounds from racemic epoxide using the same
BR0212927A (pt) * 2001-09-28 2004-10-13 Hoffmann La Roche Formas pseudopolimórficas de carvedilol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
PL371409A1 (en) 2002-01-15 2005-06-13 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
EP1499310A4 (fr) * 2002-04-30 2005-12-07 Sb Pharmco Inc Monocitrate monohydrate de carvedilol
US20050261355A1 (en) * 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
MXPA04012923A (es) * 2002-06-27 2005-03-31 Sb Pharmco Inc Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
SK285547B6 (sk) * 2002-11-08 2007-03-01 Zentiva, A. S. Spôsob prípravy Carvedilolu
EP1615888A1 (fr) * 2003-04-21 2006-01-18 Matrix Laboratories Ltd Procede de fabrication de carvedilol, forme-ii
US7482471B2 (en) * 2003-06-20 2009-01-27 Sun Pharmaceutical Industries Limited Process for preparation of 1-[9H-carbazol-4-yloxy]-3-[{2-(2-(-methoxy)phenoxy)-ethyl}-amino]-propan-2-ol
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
EP1723107A2 (fr) 2004-02-23 2006-11-22 Cadila Healthcare Ltd. Procede de preparation de carvedilol racemique
US20070191456A1 (en) * 2004-04-22 2007-08-16 Tarur Venkatasubramanian R Novel process for the preparation of 1-(9h-carbazol-4-yloxy)-3-[[2-(-methoxyphenoxy)-ethyl] amino]-propan-2-ol
GB0411273D0 (en) * 2004-05-20 2004-06-23 Cipla Ltd Process and product
PL1838670T3 (pl) * 2004-12-09 2010-03-31 Zach System Spa Sposób wytwarzania karwedilolu i jego enancjomerów
US20070043099A1 (en) * 2005-06-09 2007-02-22 Igor Lifshitz Crystalline forms of carvedilol and processes for their preparation
WO2007077111A1 (fr) * 2005-12-30 2007-07-12 F. Hoffmann-La Roche Ag Composés et méthodes pour la synthèse de carbazole
US8022094B2 (en) * 2006-06-28 2011-09-20 Teva Pharmaceutical Industries Ltd. Carvedilol phosphate
WO2008038301A1 (fr) * 2006-09-26 2008-04-03 Morepen Laboratories Limited Procédé pour la préparation de carvédilol
WO2008105794A1 (fr) * 2007-02-26 2008-09-04 Teva Pharmaceutical Industries Ltd. Procédé de purification du carvédilol ou de ses sels
CN102285910B (zh) * 2011-07-04 2013-06-19 南京工业大学 一种制备(s)-卡维地洛的方法
CN102617368B (zh) * 2012-02-27 2014-07-09 华中科技大学 一种α/β受体双重抑制剂及其盐的制备方法
US10749118B2 (en) 2014-06-26 2020-08-18 Samsung Display Co., Ltd. Heterocyclic compound and organic light-emitting device including the same
CA3192905A1 (fr) * 2020-09-17 2022-06-23 Sui Rong Wayne CHEN Methodes de traitement et/ou de prevention de la maladie d'alzheimer avec du r-carvedilol
CN116041248B (zh) * 2023-04-03 2023-06-06 成都摩诃大龙医药科技有限公司 一种具有抗癌活性的咔唑衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB1369580A (en) * 1972-08-18 1974-10-09 Boehringer Mannheim Gmbh Tricyclic diphenylamine derivatives
GB1458392A (en) * 1973-11-09 1976-12-15 Ici Ltd Optically-active 1-aryloxy-2,3-epoxypropane derivatives
US4202978A (en) * 1978-02-08 1980-05-13 Hoffmann-La Roche Inc. (S)-1-[2-(4-(2-Hydroxy-s-(1-alkylaminopropoxy)phenylalkyl]-4-phenylpiperazines
CH641147A5 (de) * 1979-01-17 1984-02-15 Sandoz Ag 3-amino-2-hydroxypropoxyaryl-derivat, seine herstellung und dieses enthaltende heilmittel.
DE3011808A1 (de) * 1980-03-27 1981-10-01 Cassella Ag, 6000 Frankfurt Verfahren zur herstellung von n-hydroxyalkylcarbazol
US4400383A (en) * 1981-12-11 1983-08-23 Burroughs Wellcome Co. Treatment of anxiety
DE3300933A1 (de) * 1983-01-13 1984-07-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten

Also Published As

Publication number Publication date
FI842046A0 (fi) 1984-05-22
US5071868A (en) 1991-12-10
US4697022A (en) 1987-09-29
DE3463768D1 (en) 1987-06-25
JPH0527622B2 (fr) 1993-04-21
DE3319027A1 (de) 1984-11-29
FI80018C (fi) 1990-04-10
IE57533B1 (en) 1993-03-24
HU193011B (en) 1987-08-28
GR81577B (fr) 1984-12-11
NO164537C (no) 1990-10-17
IL71876A (en) 1987-10-30
PT78633B (de) 1986-06-18
EP0127099B1 (fr) 1987-05-20
KR860001761B1 (ko) 1986-10-21
FI80018B (fi) 1989-12-29
CA1259071A (fr) 1989-09-05
AU2848084A (en) 1984-11-29
DK169331B1 (da) 1994-10-10
IE841295L (en) 1984-11-26
NZ208254A (en) 1988-11-29
JPS59222473A (ja) 1984-12-14
ATE27273T1 (de) 1987-06-15
DK91393D0 (da) 1993-08-06
KR840009088A (ko) 1984-12-24
AU551116B2 (en) 1986-04-17
JPH0613508B2 (ja) 1994-02-23
DK169333B1 (da) 1994-10-10
ZA843976B (en) 1985-01-30
DK255184D0 (da) 1984-05-24
NO842084L (no) 1984-11-27
DK255184A (da) 1984-11-27
PT78633A (de) 1984-06-01
US4985454A (en) 1991-01-15
ES8502683A1 (es) 1985-02-01
DK91393A (da) 1993-08-06
ES532838A0 (es) 1985-02-01
IL71876A0 (en) 1984-09-30
US4824963A (en) 1989-04-25
FI842046A (fi) 1984-11-27
EP0127099A1 (fr) 1984-12-05
HUT34160A (en) 1985-02-28
NO164537B (no) 1990-07-09
JPH05208957A (ja) 1993-08-20

Similar Documents

Publication Publication Date Title
PH22749A (en) Optically active carbazole and pharmaceutical composition containing same
DE3567870D1 (en) Xanthine derivatives, processes for their preparation and pharmaceutical compositions containing them
GB1425354A (en) Indole derivatives
ES8606880A1 (es) Un procedimiento para la preparacion de nuevos peptidos.
DE3474298D1 (en) Derivatives of 4-phenyl-4-oxo-buten-2-oic acid, their preparation, medicaments and compositions containing them
IL71068A0 (en) N-arylpiperazine derivative,its preparation and pharmaceutical compositions containing it
IL70258A (en) 1,3,4,5-tetrahydrobenzazepine and benzdiazepine derivatives,their preparation and pharmaceutical compositions containing them
US4051259A (en) Phenoxyacetic acid amide
ES8305358A1 (es) Procedimiento para la preparacion de 3-n-(2-(5-dimetilaminometilfuran-2-ilmetiltio) etil) piridincarboxamida 1-oxido.
GB846560A (en) Improvements in indole derivatives
EG16489A (en) Process for the preparation of accridanone derivatives
HUT39731A (en) Process for preparing arphamenine derivatives and pharmaceutical compositions containing such compounds